The phase II prospective, non-comparative BRAIN study (NCT00800202) investigated efficacy and safety of bevacizumab in chemotherapy-naive or pretreated patients with non-small-cell lung cancer (NSCLC) and asymptomatic untreated brain metastases, to provide data in this previously unexplored subgroup.

READ FULL ARTICLE Curated publisher From Mdlinx